Skip to content

Forte Biosciences, Inc.

FBRX

CIK 0001419041

← back to feed
Revenue (TTM)
$18.04M
−99.8% YoY Q1 Mar 2026
Net Income (TTM)
−$66.72M
−95.5% YoY Q1 Mar 2026
EPS Diluted (TTM)
−$4.56
+61.3% YoY Q1 Mar 2026
Gross Margin
—
Q1 Mar 2026
Operating Margin
-379.9%
Q1 Mar 2026
Net Margin
-369.9%
Q1 Mar 2026
Free Cash Flow (TTM)
−$41.23M
Q1 Mar 2026
Cash
$58.22M
Q1 Mar 2026
Total Debt
$22.08M
Q1 Mar 2026
Shares Outstanding
13.89M sh
Q1 Mar 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings